This study will evaluate naltrexone and cognitive-behavioral therapy treatments for alcohol dependence and post-traumatic stress disorder (PTSD). Subjects will be randomly assigned a 6-month treatment of either: 1) naltrexone alone, 2) naltrexone with PTSD psychosocial therapy, 3) a placebo with PTSD psychosocial therapy, or 4) placebo alone. An enhanced medication management intervention will accompany all treatment conditions. Follow-up assessments will be completed at 9 and 12 months after treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
165
Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
Daily dosing 100 mg for 24 weeks
Pill Placebo daily dosing 24 weeks
Center for Anxiety, University of Pennsylvania
Philadelphia, Pennsylvania, United States
Posttraumatic Stress Disorder (PTSD) Symptom Scale - Interview (PSS-I-IV)
The PSS-I-IV is a clinician-rated interview that evaluates PTSD symptoms on a frequency/severity scale corresponding to the DSM-IV symptom criteria. The measure has a total score range from 0 to 51, with higher scores indicating more severe PTSD symptoms.
Time frame: Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up)
Drinking Timeline Follow-back Interview (TFBI)
The TFBI is an interview that utilizes a calendar method to assess when and how much alcohol was consumed by the participant. At Week 0 (Pretreatment), Week 24 (Posttreatment), and Week 52 (Follow-up), alcohol consumed in the past 90 days was assessed. This measure was then used to calculate the percentage of days drinking in the past 90 days at each time point. Higher scores for percentage of days drinking indicate worse drinking outcomes.
Time frame: Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up)
Penn Alcohol Cravings Scale
The Penn Alcohol Craving Scale is a 5-item self-report measure. It assesses alcohol craving during the prior week. Total scores on this measure range from 0 to 30, with higher scores indicating a higher level of craving.
Time frame: Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.